Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Effect of interfacial serum proteins on the cell membrane disruption induced by amorphous silica nanoparticles in erythrocytes, lymphocytes, malignant melanocytes, and macrophages.

Shinto H, Fukasawa T, Yoshisue K, Tsukamoto N, Aso S, Hirohashi Y, Seto H.

Colloids Surf B Biointerfaces. 2019 Sep 1;181:270-277. doi: 10.1016/j.colsurfb.2019.05.067. Epub 2019 May 27.

PMID:
31153022
2.

Pharmacokinetics of S-1 monotherapy in plasma and in tears for gastric cancer patients.

Yasui H, Kawakami T, Kashiwagi H, Mori K, Omae K, Kasai J, Yoshisue K, Kawahira M, Tsushima T, Machida N, Fukutomi A, Yamaguchi K.

Int J Clin Oncol. 2019 Jun;24(6):660-665. doi: 10.1007/s10147-018-01387-6. Epub 2019 Apr 22.

3.

TAS-114, a First-in-Class Dual dUTPase/DPD Inhibitor, Demonstrates Potential to Improve Therapeutic Efficacy of Fluoropyrimidine-Based Chemotherapy.

Yano W, Yokogawa T, Wakasa T, Yamamura K, Fujioka A, Yoshisue K, Matsushima E, Miyahara S, Miyakoshi H, Taguchi J, Chong KT, Takao Y, Fukuoka M, Matsuo K.

Mol Cancer Ther. 2018 Aug;17(8):1683-1693. doi: 10.1158/1535-7163.MCT-17-0911. Epub 2018 May 10.

4.

Contribution of equilibrative nucleoside transporter(s) to intestinal basolateral and apical transports of anticancer trifluridine.

Takahashi K, Yoshisue K, Chiba M, Nakanishi T, Tamai I.

Biopharm Drug Dispos. 2018 Jan;39(1):38-46. doi: 10.1002/bdd.2110. Epub 2017 Dec 15.

PMID:
29055025
5.

Pharmacokinetics of initial full and subsequent reduced doses of S-1 in patients with locally advanced head and neck cancer-effect of renal insufficiency.

Yamazaki T, Tahara M, Enokida T, Wakasugi T, Arahira S, Zenda S, Motegi A, Akimoto T, Yoshisue K.

Jpn J Clin Oncol. 2017 May 1;47(5):407-412. doi: 10.1093/jjco/hyx006.

PMID:
28159957
6.

Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer.

Yoshino T, Hyodo I, Nishina T, Narahara H, Sugimoto N, Yoshisue K, Boku N.

Cancer Chemother Pharmacol. 2017 Jan;79(1):107-116. doi: 10.1007/s00280-016-3212-6. Epub 2016 Dec 8.

PMID:
27933371
7.

Exposure-dependent incorporation of trifluridine into DNA of tumors and white blood cells in tumor-bearing mouse.

Yamashita F, Komoto I, Oka H, Kuwata K, Takeuchi M, Nakagawa F, Yoshisue K, Chiba M.

Cancer Chemother Pharmacol. 2015 Aug;76(2):325-33. doi: 10.1007/s00280-015-2805-9. Epub 2015 Jun 18.

PMID:
26084259
8.

Involvement of Concentrative Nucleoside Transporter 1 in Intestinal Absorption of Trifluridine Using Human Small Intestinal Epithelial Cells.

Takahashi K, Yoshisue K, Chiba M, Nakanishi T, Tamai I.

J Pharm Sci. 2015 Sep;104(9):3146-53. doi: 10.1002/jps.24455. Epub 2015 Apr 21.

PMID:
25900515
9.

Species variation in the enantioselective metabolism of tegafur to 5-fluorouracil among rats, dogs and monkeys.

Yamamiya I, Yoshisue K, Ishii Y, Yamada H, Yoshida K.

J Pharm Pharmacol. 2014 Dec;66(12):1686-97. doi: 10.1111/jphp.12304. Epub 2014 Aug 13.

PMID:
25117829
10.

Effect of CYP2A6 genetic polymorphism on the metabolic conversion of tegafur to 5-fluorouracil and its enantioselectivity.

Yamamiya I, Yoshisue K, Ishii Y, Yamada H, Chiba M.

Drug Metab Dispos. 2014 Sep;42(9):1485-92. doi: 10.1124/dmd.114.058008. Epub 2014 Jul 7.

PMID:
25002745
11.

First-in-human, phase I dose-escalation study of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers.

Saito K, Nagashima H, Noguchi K, Yoshisue K, Yokogawa T, Matsushima E, Tahara T, Takagi S.

Cancer Chemother Pharmacol. 2014 Mar;73(3):577-83. doi: 10.1007/s00280-014-2383-2. Epub 2014 Jan 23.

PMID:
24452393
12.

Enantioselectivity in the cytochrome P450-dependent conversion of tegafur to 5-fluorouracil in human liver microsomes.

Yamamiya I, Yoshisue K, Ishii Y, Yamada H, Yoshida K.

Pharmacol Res Perspect. 2013 Oct;1(1):e00009. doi: 10.1002/prp2.9. Epub 2013 Oct 23.

13.

Involvement of concentrative nucleoside transporter 1 in intestinal absorption of trifluorothymidine, a novel antitumor nucleoside, in rats.

Okayama T, Yoshisue K, Kuwata K, Komuro M, Ohta S, Nagayama S.

J Pharmacol Exp Ther. 2012 Feb;340(2):457-62. doi: 10.1124/jpet.111.186296. Epub 2011 Nov 10.

PMID:
22076553
14.

Formation pathways of gamma-butyrolactone from the furan ring of tegafur during its conversion to 5-fluorouracil.

Yamamiya I, Yoshisue K, Matsushima E, Nagayama S.

Drug Metab Dispos. 2010 Aug;38(8):1267-76. doi: 10.1124/dmd.110.032797. Epub 2010 May 12.

PMID:
20463005
15.

Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats.

Yoshisue K, Kanie S, Nishimura T, Chikamoto J, Nagayama S.

J Pharm Pharmacol. 2009 Dec;61(12):1643-51. doi: 10.1211/jpp/61.12.0009.

PMID:
19958587
16.

The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling.

Kato M, Shitara Y, Sato H, Yoshisue K, Hirano M, Ikeda T, Sugiyama Y.

Pharm Res. 2008 Aug;25(8):1891-901. doi: 10.1007/s11095-008-9607-2. Epub 2008 May 16.

PMID:
18483837
17.

Simultaneous expression of guinea pig UDP-glucuronosyltransferase 2B21 and 2B22 in COS-7 cells enhances UDP-glucuronosyltransferase 2B21-catalyzed morphine-6-glucuronide formation.

Ishii Y, Miyoshi A, Watanabe R, Tsuruda K, Tsuda M, Yamaguchi-Nagamatsu Y, Yoshisue K, Tanaka M, Maji D, Ohgiya S, Oguri K.

Mol Pharmacol. 2001 Nov;60(5):1040-8.

PMID:
11641432
18.

Effects of 5-fluorouracil on the drug-metabolizing enzymes of the small intestine and the consequent drug interaction with nifedipine in rats.

Yoshisue K, Nagayama S, Shindo T, Kawaguchi Y.

J Pharmacol Exp Ther. 2001 Jun;297(3):1166-75.

PMID:
11356943
19.

Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro.

Ikeda K, Yoshisue K, Matsushima E, Nagayama S, Kobayashi K, Tyson CA, Chiba K, Kawaguchi Y.

Clin Cancer Res. 2000 Nov;6(11):4409-15.

20.
21.
22.

Pharmacokinetics and biological fate of 3-(2,2, 2-trimethylhydrazinium)propionate dihydrate (MET-88), a novel cardioprotective agent, in rats.

Yoshisue K, Yamamoto Y, Yoshida K, Saeki M, Minami Y, Esumi Y, Kawaguchi Y.

Drug Metab Dispos. 2000 Jun;28(6):687-94.

PMID:
10820142
23.

Purification of a phenobarbital-inducible UDP-glucuronosyltransferase isoform from dog liver which catalyzes morphine and testosterone glucuronidation.

Oguri K, Kurogi A, Yamabe K, Tanaka M, Yoshisue K, Ishii Y, Yoshimura H.

Arch Biochem Biophys. 1996 Jan 15;325(2):159-66.

PMID:
8561493

Supplemental Content

Loading ...
Support Center